Michael Kreuter

<scp>SARS</scp> ‐CoV‐2 receptor <scp>ACE</scp> 2 and <scp>TMPRSS</scp> 2 are primarily expressed in bronchial transient secretory cells

Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer et al. · The EMBO Journal · 2020 · 1K citations · Full text

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher, Tamera J. Corte, Aryeh Fischer et al. · The Lancet Respiratory Medicine · 2019 · 606 citations

Antifibrotic Therapy, Advanced Lung Disease, Pulmonary Fibrosis +3

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 490 citations · Full text

Antifibrotic Therapy, Advanced Lung Disease, Idiopathic Pulmonary Fibrosis +6

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer et al. · The EMBO Journal · 2020 · 408 citations

Viral Pathogenesis, Immunology, Infectious Respiratory Disease +5